Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332588 · ClinicalTrials.gov registry record · Phase 1
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
A Phase 1 study of HER2-positive Breast Cancer, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04332588: Recruiting Phase 1 study of HER2-positive Breast Cancer, sponsored by University of Alabama at Birmingham.
NCT04332588 is a Phase 1 study of HER2-positive Breast Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04332588, a Phase 1 study of HER2-positive Breast Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.
Primary Outcome
Compare baseline metrics from PET/MRI
Conditions Studied
Interventions
- DRUG [18F]FMISO PET/MRI imaging
Study Locations (1)
Alabama
- The University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT04332588 shows while recruiting
NCT04332588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 235-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]FMISO PET/MRI imaging is the first listed.
NCT04332588 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04332588 about?
NCT04332588 is a clinical study titled "Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI". The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and...
What is the current status of trial NCT04332588?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-03-25. Estimated completion is 2027-08.
What conditions does trial NCT04332588 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT04332588?
The interventions under investigation include: [18F]FMISO PET/MRI imaging (DRUG).
Who is sponsoring clinical trial NCT04332588?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04332588 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04332588's enrollment target sits among peer trials
25 47th of 58 higher than 11 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI